| Title |
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, March 2010
|
| DOI | 10.1007/s00280-010-1289-x |
| Pubmed ID | |
| Authors |
Dana Rathkopf, Bryan Y. Wong, Robert W. Ross, Aseem Anand, Erika Tanaka, Margaret M. Woo, Jing Hu, Andy Dzik-Jurasz, Wei Yang, Howard I. Scher |
| Abstract |
Histone deacetylase inhibitors have demonstrated anticancer activity against a range of tumors. We aimed to define the maximum tolerated dose, toxicity, activity, and pharmacokinetics of oral panobinostat, a pan-deacetylase inhibitor, alone and in combination with docetaxel for the treatment of castration-resistant prostate cancer (CRPC). |
Mendeley readers
The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| China | 1 | 2% |
| Unknown | 50 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 10 | 19% |
| Researcher | 8 | 15% |
| Student > Bachelor | 6 | 12% |
| Student > Postgraduate | 4 | 8% |
| Student > Master | 4 | 8% |
| Other | 11 | 21% |
| Unknown | 9 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 35% |
| Agricultural and Biological Sciences | 7 | 13% |
| Biochemistry, Genetics and Molecular Biology | 5 | 10% |
| Nursing and Health Professions | 3 | 6% |
| Mathematics | 1 | 2% |
| Other | 5 | 10% |
| Unknown | 13 | 25% |